Mounjaro Cost UK: Tirzepatide Pricing Guide

Live Well Weight Loss Mounjaro cost is a key consideration for anyone exploring private tirzepatide treatment in the UK. Mounjaro (tirzepatide) is an MHRA-licensed once-weekly injectable medication that supports chronic weight management by mimicking two appetite-regulating hormones, GIP and GLP-1. While NHS access exists under NICE TA1026, waiting times and eligibility criteria lead many patients to consider private providers such as Live Well Weight Loss. This article explains how tirzepatide works, what private packages typically include, and what you can expect to pay.

What Is Tirzepatide and How Does It Support Weight Loss?

Tirzepatide (Mounjaro) is an MHRA-licensed once-weekly injectable that activates both GIP and GLP-1 receptors to reduce appetite, slow gastric emptying, and support sustained weight loss alongside lifestyle changes.

Tirzepatide is a once-weekly injectable medication licensed in the UK for both type 2 diabetes and chronic weight management under the brand name Mounjaro. The Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Mounjaro for adults with obesity or overweight with at least one weight-related health condition.^[2][1] Tirzepatide has demonstrated significant weight loss efficacy in clinical trials, leading to its approval for chronic weight management.

The medication works through a dual mechanism of action by mimicking two naturally occurring hormones: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These incretin hormones regulate appetite, food intake, and glucose metabolism. By activating both GIP and GLP-1 receptors, tirzepatide enhances insulin secretion when blood glucose is elevated, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways.^[1][4] This multifaceted approach helps patients achieve sustained caloric reduction and weight loss when used alongside a reduced-calorie diet and increased physical activity.

Clinical trial data from the SURMOUNT programme showed that participants using tirzepatide alongside lifestyle modifications achieved average weight reductions of approximately 15 to 22% of their initial body weight over 72 weeks, with results varying by dose and participant characteristics.^[7][8] These figures are drawn from across the SURMOUNT trials and should be interpreted in the context of each study's design and population.

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation, which typically diminish over time as the body adjusts to treatment.^[1][19] More serious potential side effects include pancreatitis (including reports of necrotising pancreatitis), gallbladder problems, dehydration leading to acute kidney injury, and hypersensitivity reactions. Patients should seek urgent medical attention for severe persistent abdominal pain (with or without vomiting), signs of gallstones, inability to keep fluids down, or allergic reactions. People with pre-existing diabetic eye disease should be aware that worsening of diabetic retinopathy has been reported with incretin-based therapies; any new or worsening visual symptoms should prompt prompt review by a healthcare professional.

Tirzepatide is administered via subcutaneous injection once weekly, with doses gradually titrated upward (starting at 2.5 mg, then increasing to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg at minimum 4-week intervals) to improve tolerability. Patients should not increase their dose if side effects are not tolerated.

Importantly, tirzepatide can reduce the effectiveness of oral contraceptives. Women of childbearing potential should use additional non-oral or barrier contraception for 4 weeks after starting treatment and after each dose increase. The medication is not recommended during pregnancy or breastfeeding.

NHS vs Private Weight Loss Treatment: Understanding Your Options

NHS access to Mounjaro is governed by NICE TA1026 and requires specialist service referral and BMI criteria; private providers offer faster access but patients pay the full cost of medication and support.

Access to weight management medications in the UK varies significantly between NHS and private healthcare pathways. Understanding these differences is essential for patients considering tirzepatide treatment.

NHS provision of weight loss medications, including Mounjaro (tirzepatide), is governed by eligibility criteria set out in NICE Technology Appraisal TA1026, which is now published. Under the standard NICE implementation requirement, NHS commissioners in England are expected to fund recommended treatments within 3 months of guidance publication for eligible patients. However, in practice, access also depends on local Integrated Care Board (ICB) commissioning decisions and the availability of specialist weight management services. Arrangements in Scotland, Wales, and Northern Ireland are determined separately by their respective health bodies and may differ.

NHS eligibility under TA1026 typically requires:

• Treatment within a specialist weight management service

• A body mass index (BMI) of 35 kg/m² or above (or 30 kg/m² or above with at least one weight-related comorbidity)

• Lower BMI thresholds may apply for people of South Asian, Chinese, Black African, or Caribbean family background

• Demonstrated commitment to lifestyle modification

• Stopping rules apply if a patient does not achieve a specified level of weight loss after an initial treatment period; patients and clinicians should refer to TA1026 for the current criteria

Even when clinically eligible, access may be affected by specialist service waiting times and local capacity.

Private weight loss services, such as Live Well Weight Loss, offer an alternative pathway for patients who do not meet NHS criteria, face lengthy waiting times, or prefer more flexible treatment options. Private providers typically conduct comprehensive medical assessments to ensure suitability and safety, including review of medical history, current medications, pregnancy status, and contraindications.

Key advantages of private treatment include faster access, more personalised care pathways, and ongoing clinical support throughout the treatment journey. However, patients must bear the full cost of medication and associated services. It is important to verify that any private provider operates under appropriate clinical governance, with prescribing undertaken by registered healthcare professionals (doctors, nurse or pharmacist independent prescribers) and services regulated by the relevant body for their nation: the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland (HIS) in Scotland, Healthcare Inspectorate Wales (HIW) in Wales, or the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland.

Mounjaro is licensed in the UK for chronic weight management as well as for type 2 diabetes. Prescribing it for weight management through a private service is therefore within its UK licence, provided the patient meets the criteria described in the product's Summary of Product Characteristics.

What's Included in Live Well Weight Loss Tirzepatide Packages

Live Well Weight Loss tirzepatide packages typically include an initial medical assessment, prescription and home medication delivery, dose titration reviews, injection training, lifestyle guidance, and ongoing clinical support.

Private weight management services such as Live Well Weight Loss typically structure tirzepatide treatment as comprehensive care packages rather than simply dispensing medication. Understanding what is included helps patients evaluate the overall value and clinical support provided.

Most private weight loss programmes include several core components:

Initial medical consultation and assessment: A thorough evaluation by a qualified prescriber to review medical history, assess eligibility, screen for contraindications, and discuss treatment goals. This consultation should include measurement of baseline weight, BMI, blood pressure, and relevant metabolic parameters. Comprehensive assessments should also include screening for pregnancy where relevant, eating disorders, renal function, HbA1c (especially if diabetic or at risk), lipid profile, thyroid function, gallbladder and pancreatitis history, and potential drug interactions. Patients should confirm with their provider which baseline investigations are included in their package.

Prescription and medication supply: Once deemed suitable, patients receive a prescription for tirzepatide with the appropriate starting dose (2.5 mg weekly). The medication is usually supplied directly to the patient's home via registered pharmacy services, ensuring convenience and discretion.

Dose titration and monitoring: Tirzepatide requires gradual dose escalation (from 2.5 mg to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and potentially 15 mg) at minimum 4-week intervals to minimise gastrointestinal side effects and optimise efficacy. Patients should not increase their dose if side effects persist. Comprehensive packages include regular clinical reviews to monitor progress, adjust dosing, assess tolerability, and provide ongoing support. These reviews may be conducted via video consultation, telephone, or face-to-face appointments.

Patient education: This should include training on the correct use of the Mounjaro multi-dose KwikPen (including priming, needle attachment, and dose administration as described in the UK Instructions for Use), safe sharps disposal guidance, and advice on managing side effects, including hydration recommendations to prevent dehydration and acute kidney injury.

Lifestyle and nutritional guidance: Evidence-based weight management requires more than medication alone. Quality programmes incorporate dietary advice, physical activity recommendations, and behavioural support to maximise outcomes and promote sustainable lifestyle changes.

Ongoing clinical support: Access to healthcare professionals for questions, concerns, or management of adverse effects throughout the treatment period. This continuity of care is essential for patient safety and treatment adherence.

Patients should carefully review what is included in any package and ensure the provider offers genuine clinical oversight rather than simply functioning as a prescription service.

Tirzepatide Cost Through Live Well Weight Loss Services

Monthly costs for tirzepatide through Live Well Weight Loss vary by dose and plan; patients should confirm current pricing directly with the provider and verify all regulatory registrations before purchasing.

The cost of tirzepatide through private weight loss services varies depending on the provider, package structure, and level of clinical support included. Understanding the pricing model helps patients budget appropriately for treatment.

Example monthly costs for tirzepatide through Live Well Weight Loss range from £127.95–£272.95 (price-comparison listing, checked 9 October 2026) per month. Patients should verify exactly what this includes, as some services price medication separately from consultations and support. Prices shown are indicative and may have changed; always check directly with the provider for current pricing, as costs vary depending on the dose, plan, and any ongoing promotions.

Some providers offer subscription models with monthly payments, while others may require upfront payment for multi-month packages.

Tirzepatide treatment continues as long as it remains clinically beneficial and safe, with treatment duration guided by individual response and tolerability. NHS services in England follow stopping rules set out in NICE TA1026; patients and clinicians should refer to that guidance for current continuation criteria. Arrangements in Scotland, Wales, and Northern Ireland are determined by their respective health bodies.

Factors influencing cost include:

• Dose level: As treatment progresses and doses are titrated upward (from 2.5 mg to maintenance doses of 5 mg, 10 mg, or 15 mg weekly), medication costs may increase accordingly

• Package inclusions: More comprehensive programmes with enhanced nutritional support, frequent consultations, or additional services typically command higher fees

• Provider clinical governance: Services with robust medical oversight may have different pricing structures reflecting their standards of care

Patients should be cautious of significantly cheaper options that may compromise on clinical safety, use unregulated supply chains, or lack appropriate medical supervision. Always verify that the provider is registered with the appropriate regulator for their nation: the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland (HIS) in Scotland, Healthcare Inspectorate Wales (HIW) in Wales, or the Regulation and Quality Improvement Authority (RQIA) in Northern Ireland. Check that prescribers are registered with the General Medical Council (GMC), Nursing and Midwifery Council (NMC), or General Pharmaceutical Council (GPhC), and that medications are dispensed from a GPhC-registered pharmacy (or, in Northern Ireland, a pharmacy registered with the Pharmaceutical Society of Northern Ireland (PSNI)).

Some private health insurance policies may contribute towards weight management services, though coverage for medications such as tirzepatide varies between insurers. Patients should check their policy terms or contact their insurer directly to explore potential reimbursement options.

If you experience side effects from tirzepatide, report them to your healthcare provider and via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Mounjaro KwikPen 10mg solution for injection in pre-filled pen – Summary of Product Characteristics (SmPC).
2. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
3. Mounjaro – European Medicines Agency (EMA).
4. Mounjaro: INN: tirzepatide – EMA Product Information (PDF).
5. Mounjaro EPAR – Public Assessment Report.
6. Tirzepatide | Drugs | BNF – NICE.
7. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).
8. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4).
9. Tirzepatide and health-related quality of life in adults with obesity or overweight (SURMOUNT-3).
10. Tirzepatide: A Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Agonist for the Management of Type 2 Diabetes Mellitus. Am J Ther..
11. The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review. Drug Des Devel Ther..
12. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes.
13. Women on 'skinny jabs' must use effective contraception, MHRA urges in latest guidance.
14. The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on absorption of oral hormonal contraceptives.
15. About technology appraisal guidance – NICE.
16. Implementing technology appraisal guidance in the NHS (PDF).
17. Tirzepatide for managing overweight and obesity – Recommendations (TA1026).
18. Tirzepatide for managing overweight and obesity – Practical guide: prescribing, reviewing and stopping tirzepatide (TA1026).
19. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
20. The Yellow Card scheme: guidance for healthcare professionals, patients and the public.
21. Adverse reactions to drugs | Medicines guidance – BNF.

Frequently Asked Questions